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ABSTRACT 
Objective: To assess the clinical efficacy of Goksuradi gugulu, Shudha Silajeet and Dashamula 
ghruta vasti in the management of Astheela (BPH).  
Materials and Method: This is an interventional, open, perspective, non-controlled, single 
group assigned study, designed to evaluate efficacy of Ayurvedic medicine on BPH (Astheela) 
studied on 40 patients. The study period was 84 days. 
Results: MFRml/S (Maximum flow rate) at base line was 12.1400 which was increased to 
13.9475 ml/S at 84th day after treatment. Similarly the mean PVR (Post void Residual Urine) at 
base line was 147.5750ml which was reduced to 89.7500 ml after 84 days of treatment. The 
mean MLP (Median Lobe Projection) before treatment was 7.0375mm which was reduced to 
6.5300mm, which is not statistically significant. The Mean Prostate Weight at base line was 
38.0250 which was reduced to 37.9250 after treatment and was not statistically significant. The 
effect on symptoms was found to be satisfactory. The percentage of recovery in intermittent flow 
of urine was 96.15, in Poor flow of urine was 31.21. Similarly the percentage of recovery in 
incomplete emptying of bladder, dribbling of urine, retention of urine, urge incontinence, 
frequency was 95.24, 93.75, 83.34, 90, 97.44 and 92.6 respectively which was statistically 
significant. But no change in nocturnal incontinence was found. 
KEYWORDS: Benign Prostatic Hyperplasia, BPH, Astheela, Gokshuradi Guggulu, Shudha Silajit, 
Dashmool Ghruta. 
INTRODUCTION 
Benign Prostatic Hyperplasia also referred as 
Benign Prostatic Hypertrophy, is a non-malignant 
enlargement of the prostate gland affecting aging 
men and is responsible for compromises in the 
quality of life in the geriatric population[1]. 
Histologically Benign prostatic hyperplasia is 
characterized by a coalescence of atrophy and 
proliferation in prostatic glandular and stromal 
tissue. Post-mortem studies show that the first signs 
of BPH appear before the age of 40 years, followed by 
a rapid increase in prevalence with age and 80% of 
80-year-olds have evidence of BPH [2]. In Ayurveda 
this disease clinically simulate with Astheela. It is 
described under one of the 13 types of Mutraghata 
(Obstructive Uropathy)[3]. The goal of BPH treatment 
is to reduce excessive cell growth. Recent clinical 
trials have suggested that 5α-reductase inhibitors 
and long acting α1-adrenergic antagonist drugs are 
effective in the treatment of BPH. But, these drugs 
have frequent adverse effects (headache, dizziness, 
hypotension, fatigue, reduced libido, impotence, 
breast tenderness, breast enlargement, and reduced 
sperm count), which are major limitations for long-
term usage.[4] Due to these limitations, extensive 
research work was done and some Ayurvedic 
formulations have been shown beneficial in the 
management of BPH. In Ayurvedic texts so many 
drugs are available for the management of Astheela 
The drugs which are having Vrishya and Rasayan 
property that is anti-ageing action anti-inflammatory 
drugs (Shothnashak) to minimize the size of BPH, 
Vata and Kapha shamak to pacify vitiated Doshas  
and, diuretic (Mutrala) action were selected for the 
study. Gokshura, Shilajatu and Dashmulas are having 
these properties and hence these were selected.[5,6,7] 
This study was planned to evaluate the efficacy of 
Ayurvedic Medicine with Vasti (Therapeutic 
purgation) in BPH (Astheela). 
OBJECTIVES OF THE STUDY  
Primary Objective of the study is to assess the 
clinical efficacy of Goksuradi gugulu, Shudha Silajeet 
and Dashamula ghruta vasti (Therapeutic purgation) 
in the management of BPH (Astheela).  
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MATERIALS AND METHODS 
Study Design 
This is an interventional, open, perspective, 
non-controlled, single group assigned study, designed 
to evaluate efficacy of Ayurvedic medicine. The total 
treatment period was 84 days. The patients were 
recruited at the outpatient department of Central 
Ayurveda Research Institute for Cardiovascular 
Disease, New Delhi India. 
Inclusion criteria  
Male of 40-80 years of age, who understand 
and have the ability to sign written informed consent 
prior to study having moderate to severe BPH, whose 
post void residual volume (PVR) < 250ml and the 
patients AUA (American urological association) 
symptom score index mild (0-7 points) to moderate 
(8-19 points) were included in the study. 
Exclusion criteria 
Patients with prostate and bladder 
carcinoma, prostatitis, neurogenic bladder, stricture 
urethra, diabetes mellitus, vesicle calculus were 
excluded from the study. Patients with severe 
Cardiovascular, kidney or liver disorders, and 
patients indicated for surgery with refractory 
retention and recurrent or persistent gross 
hematuria were excluded from the study. 
Study procedure 
At the initial visit, a detailed medical history, 
with special emphasis on history of urinary 
symptoms (urgency, frequency, nocturia, hesitancy, 
straining, intermittency, terminal dribbling and 
sensation of incomplete voiding) was taken from all 
patients. All patients underwent a thorough systemic 
examination, which was followed by ultra-
sonography of kidney urinary bladder and prostate 
region for determining prostate size, presence of 
nodule, asymmetry and tenderness. Routine 
biochemical blood tests (Hb, TLC and DLC) and 
specific tests of renal safety like urea, creatinine was 
done for all patients. The prostate volume and Post 
void residual urine was determined by abdominal 
ultrasound and/or Trans rectalultra-sonography.  
Drug intervention 
All patients were advised to consume 1gm 
tablet of Goksuradi gugulu, Shudha Silajeet 500mg 
twice in a day after food for a period of 84 days 
followed by Dashmulghruta vasti (20ml) once in a 
day. All the medicines were procured from IMPCL 
that supplied to attached pharmacy in this Hospital. 
Method of Administration of Vasti 
On the day before administration of Vasti the 
patients were asked to take light diet. Then the 
patients were made to lie in left lateral position 
where the left lower extremity straight and right 
lower extremity flexed on knee and hip joint. The 
patient’s left hand was kept under his head. Light 
massage was done in anal region for 2 minute. Then 
20ml of luke warm Dashmool ghruta was taken in 
enema syringe. The syringe was fixed with a rubber 
catheter lubricated with Dashmool ghruta. Rubber 
catheter was inserted into the anus of the patient up 
to the length of 4-5 inches. Caution was taken not to 
enter the air in to the anus. The patients were asked 
to take deep breath while introducing the catheter 
and drug. After the administration of Vasti, patient 
was advised to lie in supine position and patient's 
buttocks were gently tapped and waist region was 
kept slightly raised. After few minute the patients 
were advised to get up from the table and take rest. 
Follow-Up and Assessment 
All patients were followed for a period of 84 
days. At each 14th day follow-up visit, the AUA 
(American urology association Table no 1) symptom 
score and prostate size was evaluated and recorded. 
A complete clinical, biochemical and ultra-
sonographic examinations was carried out at the end 
of the 84th day. The changes in subjective and 
objective parameters were enumerated in Table no 3, 
4, 5. 
Table 1: American Urological Association BPH Symptom Score Index Questionnaire 
 Not 
at 
all 
less 
than 1 
time in 
5 
less 
than  ½  
the 
time 
about  
½  the 
time 
more 
than ½ 
the time 
almost 
always 
Your 
Score 
Incomplete Emptying Over the last month 
how, often have you had a sensation of not 
emptying your bladder completely after you 
finish 
0 1 2 3 4 5  
Frequency During the last month, how 
often have you had to urinate again less 
than two hours after you finished urinating? 
0 1 2 3 4 5  
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Intermittency During the last month, how 
often have you stopped and started again 
several time when you urinate 
0 1 2 3 4 5  
Urgency During the last month, how often 
have you found it difficult to postpone 
urination? 
0 1 2 3 4 5  
Weak Stream During the last month, how 
often have you had a weak urinary stream? 
0 1 2 3 4 5  
Straining During the last month, how often 
have you had to push or strain to begin 
urination? 
0 1 2 3 4 5  
Nocturia During the last month, how many 
times did you most typically get up to 
urinate from the time you I went to bed 
until the time you got up in the morning? 
0 1 2 3 4 5  
Add the score for each number above, and write the total in the space to the right Symptom Score =  
1-7 Mild, 8-19, Moderate, 20-35 Severe.  
Adverse Events 
Patients were specifically questioned as per a pre-determined list of common symptoms. Patients were also 
encouraged to volunteer information that they considered to be adverse events (AE) or a side effect (SE).  
Withdrawals 
Patients could withdraw voluntarily or at the discretion of the Investigator.  
Table 2: Demographic Data 
Variables N (%) Mean ± SD 
Age  55.1 ± 7.96 
BMI(Kg/m2)  25.49 ± 3.12 
Habitat 
Urban 25 (62.5)  
Semi urban 14 (35)  
Rural 1 (2.5)  
Economic Status 
Above poverty Line  36 (90)  
Below poverty line 4(10)  
Occupation 
Desk Work 35 (87.5)  
Field work with physical labor 5 (12.5)  
Dietary Habits   
Veg 4 (10)  
Non Veg 36( 90)  
Prakriti 
Vataj 11(27.5)  
Pittaja 03(7.5)  
Kaphaja 15(37.5)  
Vatta pitta 03(7.5)  
Vata kaphaj 05(12.5)  
Pitta kaphaj 03(7.5)  
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RESULT 
Table 3: Showing Symptom wise Observation in Studied Case 
Symptoms Base line (n) After 84 days  Percentage of Recovery 
Hesitancy 29 02 93.10 
Difficult in micturition 39 02 94.87 
Intermittent flow of urine 26 01 96.15 
Poor flow of urine 16 11 31.25 
Incomplete emptying of bladder 21 01 95.24 
Dribbling of urine 16 01 93.75 
Retention of urine 06 01 83.34 
Nocturnal incontinence 02 02 00 
Urge incontinence 10 01 90 
Frequency 39 01 97.44 
Nocturia 27 02 92.6 
Efficacy of Trial Drugs on Outcome Measures 
The outcome measures were compared from baseline to end of the treatment. The mean total MFRml/S 
(Maximum flow rate) at base line was 12.1400 which was increased to 13.9475 ml/Sat 84th day after treatment. 
Similarly the mean PVR (Post void Residual urine) at base line was 147.5750 ml which was reduced to 89.7500 
ml after 84 days of treatment. The mean MLP (Median lobe projection) before treatment was 7.0375mm which 
was reduced to 6.5300mm after 84 days of treatment and was found statistically significant. The Mean Prostate 
Weight at base line was 38.0250 which was reduced to 37.9250 after treatment which was not statistically 
significant. The effect on symptoms on the basis of AUA score was found to be satisfactory. The percentage of 
recovery in hesitancy was 93.10 after 84 days, percentage of recovery in difficult in micturition 94.87. The 
percentage of recover in intermittent flow of urine was 96.15. The percentage of recovery in poor flow of urine 
was 31.21. Similarly the percentage of recovery in incomplete emptying of bladder, dribbling of urine, retention 
of urine, urge incontinence, frequency was 95.24, 93.75, 83.34, 90, 97.44 and 92.6 respectively. But no change 
in nocturnal incontinence was found. The subjective findings were analyzed and enumerated in Table no. 5. The 
two-tailed P value is less than 0.0001 by conventional criteria in sign and symptoms, this difference is 
considered to be extremely statistically significant so far as clinical features are concerned. So far as USG 
findings are concerned P value is significant in MFR ML/S, PVR ml. MLP, while p value is not significant in 
prostatic weight. 
Table 4: Ultra Sonographic Findings 
Variables Mean 
Std. 
Deviation 
Std. Error 
Mean 
p-value t-value Significant 
MFR 
ml/S 
BT 12.1400 3.51800 0.55624 
0.0001 2.3829 Significant 
AT 13.9475 3.26159 0.51570 
PVR 
ml. 
BT 147.5750 7.68578 1.21523 
0.0001 39.4877 Significant 
AT 89.7500 5.16770 0.81709 
MLP 
In mm. 
BT 7.0375 .56961 0.09006 
0.0003 3.7842 Significant 
AT 6.5300 .62847 0.09937 
BWT 
in mm. 
BT 5.5000 .24807 0.03922 
0.0001 18.3335 Significant 
AT 4.5775 .19934 0..03152 
PW in gm. 
BT 38.0250 1.62493 0.25692 
0.8177 0.2312 Not Significant 
AT 37.9250 2.20009 0.34786 
(MFR= Maximum flow rate, PVR= Post Void residual volume, MLP=Median lobe projection, BWT= 
Bladder wall thickness, PW=Prostate Weight. BT-Before Treatment, AT-After Treatment 
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Changes in symptoms at baseline and after 84 days of Treatment
Base line After 84 days of Treatment Series 3
Table 5: Efficacy in Clinical Features 
           Mean Std. 
Deviation 
Std. Error 
Mean 
p-value t-value Significant 
Frequency During the last 
month 
BT 2.77 0.919517 0.145388 P<0.0001 8.8903 Highly significant 
AT  0.97 0.891196 0.140910 
Intermittency  
 
BT 2.6 0.900142 0.142325 P<0.0001 9.8590 Highly significant 
AT 0.8 0.723240 0.114354 
Weak Stream  
 
BT 2.45 0.932325 0.147413 P<0.0001 10.639 Highly significant 
AT 0.58 0.594622 0.095215 
Incomplete Emptying  
 
BT 2.55 0.814924 0.128850 P<0.0001 11.234 Highly significant 
AT 0.7 0.648469 0.102532 
Nocturia 
 
BT 2.57 0.675106 0.106743 P<0.0001 13.055 Highly significant 
AT 0.7 0.607643 0.096076 
Straining  
 
BT 1.7 0.939175 0.148496 P<0.0001 5.8945 Highly significant 
AT 0.65 0.622237 0.098384 
Urgency BT 2.65 0.699816 0.110650 P<0.0001 11.932 Highly significant 
AT 0.8 0.686873 0.108604 
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DISCUSSION 
In this study effect of Gokshuradi guggulu, 
Sudha Silajeet and Dashmula ghruta vasti was tried. 
So as far as demographic data is concerned [Table -2] 
it has been found that the disease predominantly 
found in the older age group. In this study the mean 
age was 55years. The disease is more prevalent in 
higher BMI subjects. In this study the mean BMI was 
25.49. In this study the urban population was 62.5%, 
semi urban population was 35% and rural population 
was 2.5%. So far as the economic status of the 
subjects is concerned 90% subjects were above 
poverty line and only 10% subjects were below 
poverty line. In this study 87.5% of study subject’s 
occupation was desk work which indicates that the 
disease is more prevalent in sedentary lifestyle 
population. Prakriti of the subjects are also studied. 
In this study 37.5% were Kaphaj prakriti, 27.5% 
subjects were Vataj Prakriti 12% were Vatakaphaj 
Prakriti. So it can infer that the disease is Vata and 
Kapha dominated disease. There was a significant 
reduction in the mean symptom score [Table 3]. The 
ultra-sonographic examination revealed a significant 
reduction in the post-void residual urine volume 
[Table no. 4] BWT (Bladder Wall Thickness) and 
significant increase in the urinary MFR (Maximum 
Flow Rate). Gokshuradi Guggulu contains Guggulu as 
chief ingredient. Guggulu having Laghu, Tikta guna, 
katu tikta Rasa, Ushana Veerya pacifies Vata dosha. 
Due to Tikshna guna it causes Srotas shudhi.[8] It also 
contains Trikatu, due to its Tikshana guna ushana 
veerya pacifies Vata and Kapha dosha hence reduce 
the  pain.[9] Mustak having Laghu, Rukshya guna, Katu 
Tikta Rasa, Katu Vipaka & Sheeta Veerya therefore it 
has Kapha Shamaka and diuretic property[10,11] and 
hence increases the MFR and decreases the PVR. 
Gokshuradi Guggulu (Tribulus terrestris) possesses 
diuretic, anti-inflammatory, and muscle relaxation 
actions, which has been used in genitourinary 
infections, painful micturition, dysuria and benign 
prostatic hyperplasia (Singh et al., 1991; Tomova 
1987). It also possesses alpha-adrenoceptor 
antagonistic and 5-alpha reductase enzyme 
inhibitory activities. This was also reported by Sahu, 
M et. al, Medicine update 2003. The above effects are 
also possibly due to guggulsterones present in the 
drug Guggulu. It may reduce the level of pro-
inflammatory cytokines. Guggulusterone is also able 
to reduce the Cyclo-oxygenase-2 (COX2) mRNA level 
and suppress its TNFα mediated induction 
(activation)[12,]. Dasha mula ghruta possesses anti-
inflammatory property and hence reduces MLP 
(Medial Lobe Projection) and BWT (Bladder Wall 
Thickness) and also having action on prostatic 
weight. Dasha mula Ghruta also relaxes the smooth 
muscles of prostate and bladder neck hence improves 
the urine flow and reduces bladder neck obstruction, 
improves the urinary flow rate while reducing post-
void residual urine. Sudha Silajeet possesses 
antimicrobial property and is useful in controlling 
symptoms of urinary tract infections and is beneficial 
in uropathy. It additionally possesses immuno 
modulatory effects and hence inhibits prostatic 
stromal proliferation and possibly averts the 
reoccurrence of the diseases. Sudha Shilajatu has 
multipurpose therapeutic uses after administered 
with different Anupan. Rasa Tarangini gave detailed 
description of different uses of Shilajatu. If taken with 
Dashmula it cures the Mutraghat and Astheela [13]. 
CONCLUSION  
Thus, Gokshuradi Gugulu Sudha Silajeet 
followed by Dashmul ghruta vasti is effective in 
controlling the symptoms of BPH, improving the 
0
20
40
60
80
100
120
140
160
MFR ml/S PVR MLP in mm BWT in mm PW in gm
Ultrasonigraphic changes at base line and after 84 days of Treatment
BT AT Column1
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maximum flow rate. It has significant effects in 
controlling the symptoms but very negligibly reduce 
the prostate weight and it is not statistically 
significant. During the treatment no any side effects 
or, adverse effects were found. The treatment was 
well tolerated and accepted by the patients. Thus, 
these compound medicines can be considered as 
treatment of choice in the management of patients 
with symptomatic BPH. 
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